In the debate discussing whether we should de blind or not de blind, I revert back to what Dr. Jay said. It will be difficult to enroll new patients into the Leronlimab with EUA for Remdesivir and Regeneron being used for the President. That was before the approval for Remdesivir. Dr Jay is not an armchair quarterback.
I also believe next week to 10 days, FDA will approve Regeneron.